Treatment of multiple myeloma in Celje general hospital in the five-year period from 2007–2011
Abstract
We found 55 newly diagnosed patients with multiple myeloma in the five-year observation period. There were 8 to 13 new patients per year; patient’s average age was 67.8.years. 20/55 (36.4 %) of patients were under 65 years old and 19/55 (34.6 %) were 75 years or older. We assessed the international prognostic score (ISS) in most patients (50/55; 90.9 %) and cytogenetic analysis of bone marrow before initial treatment. These findings influenced our choice of regimens for initial therapy based on bortezomib and thalidomide. Treatment regimens based on melphalan and farmorubicin were used less frequently. In 19/55 (34.6 %) of patients the treatment regimen included avtologous stem-cell transplantation (ASCT). Patients treated with ASCT have longer time to progression (median 12.4 months versus 8.7 months) and better survival (44.3 months versus 33.3 months). New active agents have changed responses to treatment (partial response in 46/55 and very good partial response in 19/55 patients). In five-year period 18 patients died, most of them due to progression of the disease. Despite the era of new active agents, multiple myeloma is still incurable disease.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.